# Thomas Force

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 118 papers | 13,430 citations | 59 h-index | 115 g-index |
| 134 ext. papers | 14,868 ext. citations | 11.6 avg, IF | 6.14 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 118 | Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. *Nature Medicine*, **2006**, 12, 908-16 | 50.5 | 920 |
| 117 | Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet, The*, **2007**, 370, 2011-9 | 40 | 843 |
| 116 | Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Journal of the American Society of Echocardiography*, **2014**, 27, 911-39 | 5.8 | 722 |
| 115 | Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. *Nature Reviews Cancer*, **2007**, 7, 332-44 | 31.3 | 628 |
| 114 | Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 1063-93 | 4.1 | 526 |
| 113 | Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. *Physiological Reviews*, **2010**, 90, 1507-46 | 47.9 | 519 |
| 112 | Protein kinase cascades in the regulation of cardiac hypertrophy. *Journal of Clinical Investigation*, **2005**, 115, 527-37 | 15.9 | 476 |
| 111 | Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. *Circulation*, **2001**, 103, 670-7 | 16.7 | 359 |
| 110 | Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. *Journal of Cell Biology*, **2000**, 151, 117-30 | 7.3 | 335 |
| 109 | Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, **2011**, 13, 1-10 | 12.3 | 295 |
| 108 | Growth factors and mitogen-activated protein kinases. *Hypertension*, **1998**, 31, 152-61 | 8.5 | 295 |
| 107 | Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. *Journal of Clinical Investigation*, **2010**, 120, 3680-7 | 15.9 | 286 |
| 106 | 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. *Circulation Research*, **2004**, 95, 692-9 | 15.7 | 270 |
| 105 | Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. *Circulation*, **2008**, 118, 84-95 | 16.7 | 260 |
| 104 | Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. *Nature Reviews Drug Discovery*, **2011**, 10, 111-26 | 64.1 | 254 |
| 103 | Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. *Nature*, **1995**, 377, 750-4 | 50.4 | 212 |
| 102 | Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 4610-5 | 11.5 | 198 |

| | | | |
|---|---|---|---|
| 101 | Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. *Clinical and Translational Science*, **2009**, 2, 15-25 | 4.9 | 177 |
| 100 | Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. *Journal of Biological Chemistry*, **2000**, 275, 13571-9 | 5.4 | 177 |
| 99 | Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. *Journal of Clinical Investigation*, **2008**, 118, 3609-18 | 15.9 | 177 |
| 98 | Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. *Circulation Research*, **2010**, 106, 21-34 | 15.7 | 159 |
| 97 | Hsp72-mediated suppression of c-Jun N-terminal kinase is implicated in development of tolerance to caspase-independent cell death. *Molecular and Cellular Biology*, **2000**, 20, 6826-36 | 4.8 | 143 |
| 96 | Stress-activated protein kinases in cardiovascular disease. *Circulation Research*, **1996**, 78, 947-53 | 15.7 | 141 |
| 95 | Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. *Journal of Clinical Investigation*, **1999**, 104, 391-8 | 15.9 | 141 |
| 94 | Glycogen-Synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. *Circulation Research*, **2005**, 96, 308-18 | 15.7 | 129 |
| 93 | The GSK-3 family as therapeutic target for myocardial diseases. *Circulation Research*, **2015**, 116, 138-49 | 15.7 | 127 |
| 92 | Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. *Journal of Biological Chemistry*, **2001**, 276, 18702-9 | 5.4 | 121 |
| 91 | Integrin-linked kinase regulates endothelial cell survival and vascular development. *Molecular and Cellular Biology*, **2004**, 24, 8134-44 | 4.8 | 119 |
| 90 | Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. *European Heart Journal*, **2014**, 35, 932-41 | 9.5 | 117 |
| 89 | Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. *Circulation*, **2004**, 109, 1196-205 | 16.7 | 114 |
| 88 | CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. *Cell Cycle*, **2012**, 11, 2747-55 | 4.7 | 113 |
| 87 | The beta-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy. *Molecular and Cellular Biology*, **2006**, 26, 4462-73 | 4.8 | 113 |
| 86 | Cardiac fibroblast glycogen synthase kinase-3 regulates ventricular remodeling and dysfunction in ischemic heart. *Circulation*, **2014**, 130, 419-30 | 16.7 | 111 |
| 85 | Emerging paradigms in cardiomyopathies associated with cancer therapies. *Circulation Research*, **2013**, 113, 754-64 | 15.7 | 111 |
| 84 | c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. *Circulation Research*, **2006**, 98, 111-8 | 15.7 | 111 |

| | | | |
|---|---|---|---|
| 83 | GSK-3 is a central regulator of age-related pathologies in mice. *Journal of Clinical Investigation*, **2013**, 123, 1821-32 | 15.9 | 108 |
| 82 | Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. *Journal of Biological Chemistry*, **2000**, 275, 17838-47 | 5.4 | 107 |
| 81 | Ischemia and reperfusion enhance ATF-2 and c-Jun binding to cAMP response elements and to an AP-1 binding site from the c-jun promoter. *Journal of Biological Chemistry*, **1995**, 270, 30084-92 | 5.4 | 100 |
| 80 | Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. *Journal of Biological Chemistry*, **2009**, 284, 9643-7 | 5.4 | 99 |
| 79 | Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart. *Journal of Biological Chemistry*, **2004**, 279, 21383-93 | 5.4 | 99 |
| 78 | MICU1 motifs define mitochondrial calcium uniporter binding and activity. *Cell Reports*, **2013**, 5, 1576-1588 | 8.6 | 98 |
| 77 | Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. *American Heart Journal*, **2012**, 163, 156-63 | 4.9 | 96 |
| 76 | CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell orientation. *Journal of Cell Science*, **2010**, 123, 1274-84 | 5.3 | 92 |
| 75 | Acute reduction in functional infarct expansion with late coronary reperfusion: assessment with quantitative two-dimensional echocardiography. *Journal of the American College of Cardiology*, **1988**, 11, 192-200 | 15.1 | 91 |
| 74 | Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. *Circulation Research*, **2010**, 106, 1635-45 | 15.7 | 88 |
| 73 | Entanglement of GSK-3, -catenin and TGF-1 signaling network to regulate myocardial fibrosis. *Journal of Molecular and Cellular Cardiology*, **2017**, 110, 109-120 | 5.8 | 80 |
| 72 | Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem. *Drug Discovery Today*, **2008**, 13, 778-84 | 8.8 | 77 |
| 71 | Deletion of cytosolic phospholipase A2 promotes striated muscle growth. *Nature Medicine*, **2003**, 9, 944-51 | 30.5 | 76 |
| 70 | Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. *Circulation*, **2015**, 132, 2248-58 | 16.7 | 75 |
| 69 | Wnt signaling exerts an antiproliferative effect on adult cardiac progenitor cells through IGFBP3. *Circulation Research*, **2011**, 109, 1363-74 | 15.7 | 71 |
| 68 | A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. *Circulation Research*, **2011**, 109, 1401-9 | 15.7 | 67 |
| 67 | Why do kinase inhibitors cause cardiotoxicity and what can be done about it?. *Progress in Cardiovascular Diseases*, **2010**, 53, 114-20 | 8.5 | 65 |
| 66 | 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. *Journal of Cardiac Failure*, **2008**, 14, 245-53 | 3.3 | 65 |

| | | | |
|---|---|---|---|
| 65 | Renal ischemia/reperfusion and ATP depletion/repletion in LLC-PK(1) cells result in phosphorylation of FKHR and FKHRL1. *Kidney International*, **2003**, 64, 1189-98 | 9.9 | 65 |
| 64 | PLIP, a novel splice variant of Tip60, interacts with group IV cytosolic phospholipase A(2), induces apoptosis, and potentiates prostaglandin production. *Molecular and Cellular Biology*, **2001**, 21, 4470-81 | 4.8 | 60 |
| 63 | A novel cardioprotective p38-MAPK/mTOR pathway. *Experimental Cell Research*, **2011**, 317, 2938-49 | 4.2 | 59 |
| 62 | Serine 58 of 14-3-3zeta is a molecular switch regulating ASK1 and oxidant stress-induced cell death. *Molecular and Cellular Biology*, **2009**, 29, 4167-76 | 4.8 | 59 |
| 61 | Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy. *Circulation Research*, **2016**, 118, 1208-22 | 15.7 | 55 |
| 60 | Role of phosphoinositide 3-kinase in monocyte recruitment under flow conditions. *Journal of Biological Chemistry*, **2001**, 276, 26846-51 | 5.4 | 55 |
| 59 | Targeting GSK-3 family members in the heart: a very sharp double-edged sword. *Journal of Molecular and Cellular Cardiology*, **2011**, 51, 607-13 | 5.8 | 54 |
| 58 | Sorafenib cardiotoxicity increases mortality after myocardial infarction. *Circulation Research*, **2014**, 114, 1700-1712 | 15.7 | 50 |
| 57 | Cancer genetics and the cardiotoxicity of the therapeutics. *Journal of the American College of Cardiology*, **2013**, 61, 267-74 | 15.1 | 49 |
| 56 | Glycogen synthase kinase-3□limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death. *Circulation*, **2012**, 125, 65-75 | 16.7 | 48 |
| 55 | Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. *Journal of Biological Chemistry*, **2003**, 278, 23630-8 | 5.4 | 47 |
| 54 | Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. *Science Translational Medicine*, **2013**, 5, 207ra141 | 17.5 | 45 |
| 53 | GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. *Journal of Clinical Investigation*, **2010**, 120, 2280-91 | 15.9 | 44 |
| 52 | Nerve growth factor decreases soluble guanylate cyclase in rat pheochromocytoma PC12 cells. *Journal of Biological Chemistry*, **1997**, 272, 6038-43 | 5.4 | 44 |
| 51 | Targeted deletion of integrin-linked kinase reveals a role in T-cell chemotaxis and survival. *Molecular and Cellular Biology*, **2005**, 25, 11145-55 | 4.8 | 44 |
| 50 | In reply to Œardiotoxicity of the cancer therapeutic agent imatinib mesylateQ*Nature Medicine*, **2007**, 13, 15-16 | 50.5 | 43 |
| 49 | Cardiomyocyte-specific deletion of Gsk3□mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. *Journal of the American College of Cardiology*, **2014**, 64, 696-706 | 15.1 | 42 |
| 48 | Helix-loop-helix protein p8, a transcriptional regulator required for cardiomyocyte hypertrophy and cardiac fibroblast matrix metalloprotease induction. *Molecular and Cellular Biology*, **2007**, 27, 993-1006 | 4.8 | 42 |

| | | | |
|---|---|---|---|
| 47 | In vivo prediction of the transmural extent of experimental acute myocardial infarction using contrast echocardiography. *Journal of the American College of Cardiology*, **1986**, 8, 143-9 | 15.1 | 42 |
| 46 | Activation of beta-catenin signaling pathways by classical G-protein-coupled receptors: mechanisms and consequences in cycling and non-cycling cells. *Cell Cycle*, **2006**, 5, 2295-300 | 4.7 | 39 |
| 45 | The GCK II and III subfamilies of the STE20 group kinases. *Frontiers in Bioscience - Landmark*, **2007**, 12, 850-9 | 2.8 | 39 |
| 44 | Role of integrin-linked kinase in leukocyte recruitment. *Journal of Biological Chemistry*, **2002**, 277, 16371-5 | 5.4 | 38 |
| 43 | HSP72 can protect cells from heat-induced apoptosis by accelerating the inactivation of stress kinase JNK. *Cell Stress and Chaperones*, **2000**, 5, 139-47 | 4 | 38 |
| 42 | Activation of the Ste20-like oxidant stress response kinase-1 during the initial stages of chemical anoxia-induced necrotic cell death. Requirement for dual inputs of oxidant stress and increased cytosolic [Ca2+]. *Journal of Biological Chemistry*, **1997**, 272, 29372-9 | 5.4 | 37 |
| 41 | SOK1 translocates from the Golgi to the nucleus upon chemical anoxia and induces apoptotic cell death. *Journal of Biological Chemistry*, **2008**, 283, 16248-58 | 5.4 | 37 |
| 40 | Stretch-activated pathways and left ventricular remodeling. *Journal of Cardiac Failure*, **2002**, 8, S351-8 | 3.3 | 36 |
| 39 | Glycogen synthase kinase-3beta -- actively inhibiting hypertrophy. *Trends in Cardiovascular Medicine* , **2007**, 17, 91-6 | 6.9 | 32 |
| 38 | Gene 33/RALT is induced by hypoxia in cardiomyocytes, where it promotes cell death by suppressing phosphatidylinositol 3-kinase and extracellular signal-regulated kinase survival signaling. *Molecular and Cellular Biology*, **2006**, 26, 5043-54 | 4.8 | 31 |
| 37 | Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. *Cardiovascular Research*, **2019**, 115, 966-977 | 9.9 | 30 |
| 36 | Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55. *Journal of Biological Chemistry*, **2013**, 288, 22481-92 | 5.4 | 30 |
| 35 | Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. *PLoS ONE*, **2016**, 11, e0145937 | 3.7 | 25 |
| 34 | Mitogen-activated protein kinases and transcriptional responses in renal injury and repair. *Current Opinion in Nephrology and Hypertension*, **1998**, 7, 425-33 | 3.5 | 22 |
| 33 | Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point. *Drug Discovery Today Disease Mechanisms*, **2010**, 7, e123-e127 | | 21 |
| 32 | Molecular scaffolds regulate bidirectional crosstalk between Wnt and classical seven-transmembrane-domain receptor signaling pathways. *Science's STKE: Signal Transduction Knowledge Environment*, **2007**, 2007, pe41 | | 21 |
| 31 | Cardiomyocyte SMAD4-Dependent TGF-β Signaling is Essential to Maintain Adult Heart Homeostasis. *JACC Basic To Translational Science*, **2019**, 4, 41-53 | 8.7 | 20 |
| 30 | Calcineurin inhibitors and cardiac hypertrophy. *Lancet, The*, **1999**, 353, 1290-2 | 40 | 19 |

| | | | |
|---|---|---|---|
| 29 | Cardiotoxicity due to cancer therapy. *Texas Heart Institute Journal*, **2011**, 38, 253-6 | 0.8 | 18 |
| 28 | 21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine. *JACC Basic To Translational Science*, **2016**, 1, 386-398 | 8.7 | 18 |
| 27 | Inhibition of GSK-3 to induce cardiomyocyte proliferation: a recipe for in situ cardiac regeneration. *Cardiovascular Research*, **2019**, 115, 20-30 | 9.9 | 18 |
| 26 | Recent insights into cardiac hypertrophy and left ventricular remodeling. *Current Heart Failure Reports*, **2006**, 3, 14-8 | 2.8 | 17 |
| 25 | Cytosolic phospholipase A(2)protects against ischemia/reperfusion injury in the heart. *Clinical and Translational Science*, **2011**, 4, 236-42 | 4.9 | 16 |
| 24 | A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate. *PLoS ONE*, **2017**, 12, e0169964 | 3.7 | 16 |
| 23 | Group IVA Cytosolic Phospholipase A2 Regulates the G2-to-M Transition by Modulating the Activity of Tumor Suppressor SIRT2. *Molecular and Cellular Biology*, **2015**, 35, 3768-84 | 4.8 | 15 |
| 22 | Spatial and temporal variability in the pattern of recovery of ventricular geometry and function after acute occlusion and reperfusion. *American Heart Journal*, **1994**, 127, 1231-41 | 4.9 | 15 |
| 21 | Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. *Circulation Journal*, **2014**, 78, 1514-9 | 2.9 | 14 |
| 20 | Quantitative Methods for Analyzing Regional Systolic Function with Two-Dimensional Echocardiography. *Echocardiography*, **1986**, 3, 319-331 | 1.5 | 14 |
| 19 | Cardiomyocyte-GSK-3promotes mPTP opening and heart failure in mice with chronic pressure overload. *Journal of Molecular and Cellular Cardiology*, **2019**, 130, 65-75 | 5.8 | 13 |
| 18 | Cardiomyocyte-specific deletion of GSK-3leads to cardiac dysfunction in a diet induced obesity model. *International Journal of Cardiology*, **2018**, 259, 145-152 | 3.2 | 12 |
| 17 | Apoptosis Signal-Regulating Kinase/Nuclear Factor-B. *Circulation*, **2002**, 105, 402-404 | 16.7 | 10 |
| 16 | Cardiomyocyte Homeodomain-Interacting Protein Kinase 2 Maintains Basal Cardiac Function via Extracellular Signal-Regulated Kinase Signaling. *Circulation*, **2019**, 140, 1820-1833 | 16.7 | 9 |
| 15 | Imatinib activates pathological hypertrophy by altering myocyte calcium regulation. *Clinical and Translational Science*, **2014**, 7, 360-7 | 4.9 | 8 |
| 14 | Introduction to cardiotoxicity review series. *Circulation Research*, **2010**, 106, 19-20 | 15.7 | 8 |
| 13 | Exercise Testing and Ambulatory Monitoring in Patients With Preexcitation Syndrome. *Archives of Internal Medicine*, **1981**, 141, 88 | | 8 |
| 12 | Rab-GTPase binding effector protein 2 (RABEP2) is a primed substrate for Glycogen Synthase kinase-3 (GSK3). *Scientific Reports*, **2017**, 7, 17682 | 4.9 | 4 |

| | | | |
|---|---|---|---|
| 11 | Protein Kinase Signaling at the Crossroads of Myocyte Life and Death in Ischemic Heart Disease. *Drug Discovery Today: Therapeutic Strategies*, **2012**, 9, e173-e182 | | 4 |
| 10 | Nicotinamide riboside kinase-2 alleviates ischemia-induced heart failure through P38 signaling. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2020**, 1866, 165609 | 6.9 | 4 |
| 9 | Response by Zhou et al to Letter Regarding Article, "Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy". *Circulation Research*, **2016**, 119, e29-e30 | 15.7 | 3 |
| 8 | Mechanisms of Endothelin-Induced Mitogenesis in Vascular Smooth Muscle **1998**, 121-166 | | 3 |
| 7 | Targeted disruption of glycogen synthase kinase-3 in cardiomyocytes attenuates cardiac parasympathetic dysfunction in type 1 diabetic Akita mice. *PLoS ONE*, **2019**, 14, e0215213 | 3.7 | 2 |
| 6 | Cardiotoxicity associated with sunitinib AuthorsQreply. *Lancet, The*, **2008**, 371, 1245 | 40 | 2 |
| 5 | Calcified left atrial mass associated with mitral valve prolapse. *American Heart Journal*, **1986**, 111, 1205-7 | 4.9 | 2 |
| 4 | The Heart Failure Society of America in 2020: a vision for the future. *Journal of Cardiac Failure*, **2012** , 18, 90-3 | 3.3 | 0 |
| 3 | Protein Kinases in the Heart: Lessons Learned from Targeted Cancer Therapeutics **2012**, 689-696 | | |
| 2 | Cardiac Hypertrophy **2006**, 146-156 | | |
| 1 | Postextrasystolic potentiation during acute myocardial infarction: predicting presence of viable myocardium. *American Journal of Cardiology*, **1985**, 56, 1003-4 | 3 | |